Event JSON
{
"id": "10e0d34dc7a4827bd39a618a4efdd1a62b0380bd1fa478b9684ffb953710bb92",
"pubkey": "af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"created_at": 1734450988,
"kind": 1,
"tags": [
[
"r",
"https://en.globes.co.il/en/article-1001497039#utm_source=RSS"
],
[
"subject",
"Teva jumps sharply on bowel disease drug results"
],
[
"published_at",
"1734457517"
],
[
"image",
"https://res.cloudinary.com/globes/image/upload/t_800X392/v1658892717/direct/shutterstock_1795020259_afq1af.jpg"
],
[
"p",
"af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://res.cloudinary.com/globes/image/upload/t_800X392/v1658892717/direct/shutterstock_1795020259_afq1af.jpg"
],
[
"t",
"Israel:perspective"
],
[
"summary",
"Teva reported that the trial met its primary endpoints in ulcerative colitis and Crohn's disease, the most common forms of inflammatory bowel disease. The company plans to initiate Phase 3 development for treating inflammatory bowel diseases, which are characterized by chronic inflammation in the digestive system. The treatment effect was consistent across subgroups, and detailed results are expected to be presented at a scientific forum in 2025."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpq4728avdv9222s66gew76s5fedw9u42d2t8ynytnu8k5zvnswnpuq7qxnev\nhttps://res.cloudinary.com/globes/image/upload/t_800X392/v1658892717/direct/shutterstock_1795020259_afq1af.jpg\nTeva reported that the trial for Dukaviyug, which it is developing with Sanofi, met its endpoints in ulcerative colitis and Crohn's disease, the most common forms of inflammatory bowel disease.\nhttps://en.globes.co.il/en/article-1001497039#utm_source=RSS",
"sig": "be8e05c4d7288a7590deac6de121ebf16fe1584c5aa84e7818a6dee8a334be7488bb555827c49955c9434e51b25ad193f520246fa372cf89fbef2ec174a98825"
}
